Suppr超能文献

高泌乳素血症患者使用溴隐亭治疗的结果

Outcome of treatment with bromocriptine in patients with hyperprolactinaemia.

作者信息

al-Suleiman S A, Najashi S, Rahman J, Rahman M S

机构信息

Department of Obstetrics and Gynecology, King Faisal University, College of Medicine, Dammam, Saudi Arabia.

出版信息

Aust N Z J Obstet Gynaecol. 1989 May;29(2):176-9. doi: 10.1111/j.1479-828x.1989.tb01712.x.

Abstract

Results in 136 hyperprolactinaemic women who presented with infertility, amenorrhoea, menstrual irregularities and/or galactorrhoea are reported. There was radiographic evidence of pituitary microadenoma in 21 (15.4%) patients and 5 (3.7%) had macroadenoma. Four patients were taking antidepressants, 2 antihypertensive drugs and 7 had taken oral contraceptives for a period of 6 months to 5 years. The remaining patients had no obvious cause for elevated prolactin levels. Patients with pituitary adenoma had a significantly higher (p less than 0.001) baseline serum prolactin level (182 +/- 4.6 ng/ml) than those with no adenoma (59.2 +/- 4.2 ng/ml). All patients in the study were treated with bromocriptine (2.5-10 mg) to normalize serum prolactin or to achieve a pregnancy. The patients without an adenoma required a significantly smaller dose of bromocriptine (2.5-5.0 mg) (p less than 0.005) than those with an adenoma. Galactorrhoea disappeared in all 64 patients within 2-4 months of treatment, sixty-six (71%) of the 93 patients who desired pregnancy achieved it within 3 to 8 months of bromocriptine therapy; 32 of these patients received additional treatment with clomiphene and human chorionic gonadotrophins for induction of ovulation. In the remaining 70 patients menstruation became regular and ovulation was evident in 40% of them. There was no significant difference in the pregnancy rate between the patients with or without pituitary adenoma. Similarly, presence of galactorrhoea or a high level of prolactin did not influence the pregnancy rate. No complications were observed during pregnancy related to pituitary adenomas; 8 (12%) pregnancies ended in first trimester abortion. No lethal congenital fetal abnormalities were observed in the patients treated with bromocriptine.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

报告了136例高催乳素血症女性的结果,这些女性表现为不孕、闭经、月经不规律和/或溢乳。21例(15.4%)患者有垂体微腺瘤的影像学证据,5例(3.7%)有大腺瘤。4例患者正在服用抗抑郁药,2例服用降压药,7例服用口服避孕药6个月至5年。其余患者催乳素水平升高无明显原因。垂体腺瘤患者的基线血清催乳素水平(182±4.6 ng/ml)显著高于无腺瘤患者(59.2±4.2 ng/ml)(p<0.001)。研究中的所有患者均接受溴隐亭(2.5 - 10 mg)治疗以使血清催乳素正常化或实现妊娠。无腺瘤患者所需的溴隐亭剂量(2.5 - 5.0 mg)显著低于有腺瘤患者(p<0.005)。所有64例患者的溢乳在治疗2 - 4个月内消失,93例希望妊娠的患者中有66例(71%)在溴隐亭治疗3至8个月内实现妊娠;其中32例患者接受了克罗米芬和人绒毛膜促性腺激素的额外治疗以诱导排卵。其余70例患者月经恢复正常,其中40%有排卵迹象。有或无垂体腺瘤患者的妊娠率无显著差异。同样,溢乳或高催乳素水平的存在并不影响妊娠率。妊娠期间未观察到与垂体腺瘤相关的并发症;8例(12%)妊娠在孕早期流产。接受溴隐亭治疗的患者未观察到致命的先天性胎儿异常。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验